தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் இன்க் Today - Breaking & Trending Today

Johnson & Johnson : New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy

Johnson & Johnson : New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , South Korea , Craig Tendler , Jennifer Mcintyre , Catherinea Shu , Ania Diantonio , Global Medical Affairs , National Cancer Institute , Janssen Biotech Inc , National Comprehensive Cancer Network Inc , Janssen Research Development , Janssen Pharmaceutical Companies Of Johnson , Thoracic Medical Oncology Service , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Slate Development , Columbia University Herbert Irving Comprehensive Cancer Center , Drug Administration , World Health Organization , Yuhan Corporation , Exchange Commission , Companies Of Johnson , European Society For Medical Oncology , Janssen Pharmaceutical Companies , European Society , Medical Oncology ,

FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

Share this article
Share this article
LONDON, April 22, 2021 /PRNewswire/ GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company s Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ....

City Of , United Kingdom , United States , United Kingdom General , Kathleen Quinn , Jeff Mclaughlin , Simon Steel , Sonya Ghobrial , Prnewswire Glaxosmithkline , Mick Readey , Tim Foley , James Dodwell , Hal Barron , Kristen Neese , Durham Jn Smith , Gynecologic Oncology At Levine Cancer Institute , National Cancer Institute , National Comprehensive Cancer Network Inc , Tesaro Inc , Drug Administration , Health Professional Version , Atrium Health , Company Annual Report On Form , Our Risk Of Cancer Empowered , American Cancer Society , Clinical Practice Endometrial Cancer Working Group ,

EUSA Pharma: SYLVANT (siltuximab) Recommended by the National Comprehensive Cancer Network (NCCN) as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) regardless of histopathologic subtype

(1)
EUSA Pharma (UK) Limited (
EUSA Pharma ), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network
(NCCN
) for B-Cell Lymphomas to include siltuximab (SYLVANT
) as the preferred primary treatment for patients with human immunodeficiency virus-negative [HIV(-)] and human herpesvirus 8-negative [HHV-8(-)] multicentric Castleman disease (MCD), also known as idiopathic multicentric Castleman disease (iMCD), regardless of histopathologic subtype.
1 Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues.
2,3 The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype. ....

Hemel Hempstead , United Kingdom , United States , Kostenloser Wertpapierhandel , Lee Morley , David Fajgenbaum , Rebecca Kerr , National Comprehensive Cancer Network Inc , European Commission , Drug Administration , Castleman Disease Collaborative Network , Eusa Pharma United Kingdom Limited , University Of Pennsylvania , Pharma United Kingdom Ltd , National Comprehensive Cancer Network , National Comprehensive Cancer , Clinical Practice Guidelines , B Cell Lymphomas , Chief Executive Officer , Assistant Professor , Translational Medicine Human Genetics , Co Founder Executive Director , Castleman Disease Collaborative , Usage See , Product Characteristics , Practice Guidelines ,

Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA
® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST). ....

United States , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , Asia Pacific , American Society Of Clinical Oncology , National Comprehensive Cancer Network Inc , Monitoring Committee , Drug Administration , American Urological Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Exchange Commission , Prostate Cancer Panel , Companies Of Johnson , American Society , Clinical Oncology , Cancers Symposium , Rapid Abstract Session , Prostate Cancer , Clinical Oncology Genitourinary Cancers Symposium , New England Journal , North America , Latin America ,

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA
® and ZYTIGA
® plus prednisone (control arm).
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST). ....

United States , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , None Of The Janssen Pharmaceutical Companies , National Comprehensive Cancer Network Inc , World Health Organization , Drug Administration , American Urological Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Exchange Commission , Prostate Cancer Panel , Companies Of Johnson , European Commission On , American Society , Clinical Oncology , Cancers Symposium , Oral Abstract Session , Prostate Cancer , Practice Guidelines , Castration Resistant Prostate Cancer , Evidence Level Grade , National Comprehensive Cancer Network ,